You are here:Home-Research Areas-Other Indications-Anemia

Request The Product List ofAnemia Anemia

Cat. No. Product Name CAS No. Information
PC-61443

Rivipansel sodium

1189037-60-2

Rivipansel sodium (GMI-1070, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

Anemia

Phase 3 Clinical

PC-61286

GMI-1070

927881-99-0

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively; predominantly inhibits E-selectin-mediated adhesion and dramatically inhibits sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival; a valuable novel therapeutic intervention for acute sickle cell crises.

Anemia

Phase 3 Clinical

PC-42346

Vadadustat

1000025-07-9

Vadadustat (PG-1016548, AKB-6548) is a novel, potent, orally active HIF-PH inhibitor in development for the treatment of anemia in both nondialysis-dependent (NDD) and dialysis-dependent CKD; induces endogenous erythropoietin synthesis and enhances iron mobilization.

Anemia

Phase 3 Clinical

PC-45387

Daprodustat

960539-70-2

A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease.

Anemia

Phase 3 Clinical

PC-45522

GBT-440

1446321-46-5

A new potent allosteric effector of sickle cell hemoglobin; increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions; orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150.

Anemia

Phase 3 Clinical

PC-43531

Roxadustat

808118-40-3 Roxadustat (FG4592, FG-4592) is a potent, orally available HIF prolyl hydroxylase (HIF-PHD) with IC50 of 591.4 nM; FG-4592 stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, demonstrates potential for treatment of anemia.

Anemia

Phase 3 Clinical

PC-43140

Molidustat

1154028-82-6 Molidustat (BAY 85-3934) is an orally active small molecule inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH) with IC50 of 480 nM, 280 nM and 450 nM for PHD1, PHD2, and PHD3, respectively; causes dose-dependent production of erythropoietin (EPO) in healthy Wistar rats and cynomolgus monkeys, increases hemoglobin levels and shows effectivity in the treatment of renal anemia in rats with impaired kidney function, resultsin normalization of hypertensive blood pressure in rat model of CKD.

Anemia

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com